Trial Profile
A randomized, open-label, single-dose, three-period, crossover study to demonstrate the bioequivalence of the fixed dose combination (FDC) of Coreg CR [carvedilol] and lisinopril to Coreg CR and Zestril [lisinopril].
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Carvedilol/lisinopril (Primary) ; Carvedilol; Lisinopril
- Indications Angina pectoris; Heart failure; Hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 23 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2007 New trial record.